Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Novo won the U.S. Food and Drug Administration's approval in 2024 to use Wegovy to reduce the risk of cardiovascular death, ...

The oral version of Rybelsus failed to meet its primary goal in two late-stage clinical trials, which aimed to evaluate its ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Investors take the value of the company's shares back to where they stood in July 2021 following Novo Nordisk's announcement.

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

The results from the two trials of early-stage patients, called EVOKE and EVOKE+, are another setback for the Danish drugmaker and new CEO Mike Doustdar, which had seen booming success, driven by ...

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive ...